抗Payload抗體
抗體藥物偶聯物(ADCs)是一種新型的抗癌藥物,結合了單克隆抗體和小分子毒素,具有高度靶向性和高毒素性。由于ADC 給藥后會發生payload 的解結合,導致未結合的payload 的增加和ADC 成分(即DAR 分布)的變化。因此,對偶聯的抗體和偶聯在抗體上的payload 的體內定量分析有助于評估ADC 藥效,并有助于評估payload 在靶點的暴露情況,且確定DAR 分布和平均DAR 值的變化對于提供ADC 的穩定性等整體評估至關重要。
華美CUSABIO推出適用于臨床前及臨床階段抗體藥有效研究工具——抗Payload抗體。可用于ADC藥物的血漿/血清動力學分析、藥物結合親和力的測定、DAR值分析以及ADC藥物的療效評估。
抗Payload抗體類型
ADC 各成分與其對應分析方法
ADC 的生物分析需要一種綜合的生物分析方法,包括配體結合測定和高效液相色譜串聯質譜聯用技術(LC-MS/MS),分別用于大分子和小分子生物分析。抗payload 抗體在ADC 的免疫原性分析中至關重要,用于免疫原性分析的橋接檢測方法(Bridging LBA)。
Analyte Type | Description | Typical analytical platforms |
---|---|---|
Total antibody | Total antibody (conjugated or unconjugated) | LBA, hybrid LC-MS/MS |
Total ADC | Total conjugated antibody (DAR > 1)OR | LBA |
Total payload conjugated to antibody (DAR > 1) | LBA hybrid LC-MS/MS | |
Unconjugated payload | Payload not conjugated to antibody | LC-MS/MS |
(Faria et al., 2022. Doi:10.1007/978-3-030-97193-9_3)
ADC有效荷載-Anti DXD

圖1. DXD-新一代ADC最具前景的有效荷載 [1]
應用場景
藥代動力學(PK)分析
偶聯DAR值定性分析
免疫原性分析
臨床前及臨床階段抗藥物抗體開發
產品優勢
高純度
純度經SDS-PAGE驗證大于90%
高特異性
能夠特異性識別小分子毒素
高靈敏度,高親和性
經ADC藥物結合驗證表現出顯著活性
易于檢測,節省成本
經過HRP標記的抗DXD抗體方便檢測,且無需再與二抗結合
專業技術團隊
24小時內回復您的任何售前或售后問題
產品列表
產品名稱 | 產品貨號 | 應用類型 | 純化方法 |
---|---|---|---|
DXD Recombinant Monoclonal Antibody | CSB-RA996977I1m | ELISA | Affinity-chromatography |
DXD Recombinant Monoclonal Antibody | CSB-RA996977I1h | ELISA | Affinity-chromatography |
DXD Monoclonal Antibody | CSB-MA996977I1m | ELISA | >95%, Protein G purified |
DXD Monoclonal Antibody | CSB-MA996977I2m | ELISA | >95%, Protein G purified |
DXD Monoclonal Antibody, HRP conjugated | CSB-MA996977I1m-B | ELISA | >95%, Protein G purified |
DXD Monoclonal Antibody, HRP conjugated | CSB-MA996977I2m-B | ELISA | >95%, Protein G purified |
DM1 Monoclonal Antibody | CSB-MA989454I0m | ELISA | >95%, Protein G purified |
DM1&DM4 Monoclonal Antibody | CSB-MA989811I0m | ELISA | >95%, Protein G purified |
DM1&DM4 Monoclonal Antibody | CSB-MA989811I1m | ELISA | >95%, Protein G purified |
DM1&DM4 Monoclonal Antibody | CSB-MA989811I2m | ELISA | >95%, Protein G purified |
DM1&DM4 Monoclonal Antibody | CSB-MA989811I3m | ELISA | >95%, Protein G purified |
Eribulin Recombinant Monoclonal Antibody | CSB-RA943989I1m | ELISA | Affinity-chromatography |
Eribulin Monoclonal Antibody | CSB-MA943989I1m | ELISA | >95%, Protein G purified |
MMAE&MMAF Recombinant Monoclonal Antibody | CSB-RA903890I1m | ELISA | Affinity-chromatography |
MMAE&MMAF Monoclonal Antibody | CSB-MA903890I1m | ELISA | >95%, Protein G purified |
SN38 Recombinant Monoclonal Antibody | CSB-RA187707I1m | ELISA | Affinity-chromatography |
SN38 Monoclonal Antibody | CSB-MA187707I1m | ELISA | >95%, Protein G purified |
驗證數據
(Code: CSB-MA996977I2m)

The Mouse Anti-DXD Antibody (Code: CSB-MA996977I2m) has a purity of more than 90% as determined by SEC-HPLC and SDS-PAGE.
(Code: CSB-MA943989I1m)

The Mouse Anti-DXD Antibody (Code: CSB-MA943989I1m) has a purity of more than 98% as determined by SEC-HPLC and SDS-PAGE.
(Code: CSB-MA903890I1m)

Activity: Measured by its binding ability in a functional ELISA. Immobilized Disitamab vedotin (Synonyms: RC48) at 2 μg/mL can bind Anti-MMAE antibody, the EC50 is 11.65 to 15.97 ng/mL.
(Code: CSB-MA996977I2m)

Activity: Measured by its binding ability in a functional ELISA. Immobilized T-DXd(DS-8201) at 2 μg/mL can bind Anti-DXD antibody, the activity was 4-5 times that of other companies.
定制服務
華美生物已研發多種高純度、高靈敏度,高親和力的抗Payload抗體,可用于ADC藥物的臨床前及臨床階段DAR值和PK分析,可提供定制化的抗Payload抗體,以滿足客戶的個性化需求。
參考文獻:
[1] Kumar, Seema, ed. An Introduction to Bioanalysis of Biopharmaceuticals. Vol. 57. Springer Nature, 2022.